<DOC>
	<DOCNO>NCT02237846</DOCNO>
	<brief_summary>Allogeneic human umbilical cord tissue-derived stem cell inject intravenously ( IV ) per day 3 day intra-articularly safe induce therapeutic effect osteoarthritis ( OA ) patient .</brief_summary>
	<brief_title>Clinical Study Umbilical Cord Tissue Mesenchymal Stem Cells ( UC-MSC ) Treatment Osteoarthritis</brief_title>
	<detailed_description>The propose study ass primarily safety secondary efficacy endpoint allogeneic umbilical cord mesenchymal stem cell ( UC-MSC ) administer 40 patient OA . Arm 1 receive one intra-articular injection UC-MSC knee Arm 2 receive IV UC-MSC per day 3 consecutive day . The primary objective trial freedom treatment associate adverse event 3 12 month post treatment . Secondary objective efficacy assess baseline , 3 12 month post treatment quantify base Western Ontario McMaster osteoarthritis index ( WOMAC ) .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<criteria>Signed informed consent subject . Age great equal 18 year Ability understand plan treatment . Idiopathic secondary osteoarthritis knee grade 2 , 3 , 4 radiographic severity , define modify KellgrenLawrence classification Pregnant lactate woman Women childbearing potential unwilling use two form contraception Cognitively impaired adult . Presence large meniscal tear ( `` bucket handle '' tear ) , detect clinical examination magnetic resonance imaging . Inflammatory postinfectious arthritis . More 5 degree varus valgus deformity . Kellgren Lawrence grade 4 osteoarthritis two compartment ( medial lateral compartment tibiofemoral joint patellofemoral compartment ) persons 60 year age . Intraarticular corticosteroid injection within previous 3 month . A major neurologic deficit . Serious medical illness life expectancy le 1 year . Prior admission substance abuse Body Mass Index ( BMI ) 40 kg/m2 great Patient receive experimental medication participate another clinical study within 30 day sign informed consent In opinion investigator sponsor patient unsuitable cellular therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>osteoarthritis</keyword>
	<keyword>knee</keyword>
	<keyword>stem cell</keyword>
	<keyword>mesenchymal</keyword>
	<keyword>umbilical cord</keyword>
</DOC>